Exinda Therapeutics

Continuous Innovation to Enhance Therapeutics

Exinda Therapeutics

Dedicated to developing pharmaceuticals in oncology and immunomodulation.

Novel & Proprietary Compositions

Patent protected compositions

Continuous Manufacturing Processes

Quality by Design (QbD)

WORLDWIDE PATENTS:

0

All Major Countries

USFDA Orphan Drug Designation for CLL

Most Major Blood Cancer Indications

ABOUT EXINDA THERAPEUTICS

Cutting-Edge Biopharmaceutical Research

We are a private clinical-stage biopharmaceutical company developing innovative and patent protected therapeutics for oncology and diseases of the immune system, with the goal of transforming patients’ lives.

Our Team has a collective experience of 160 years in:

  • Drug Development
  • Drug Commercialization
  • Patents & IP
  • cGMP Manufacturing & Process Development
  • Orphan Drugs & Rare Diseases
  • Business / Corporate Development
  • Mergers & Acquisitions
  • Strategic Planning for Pharmaceuticals

Blood Cancer Therapeutics

Our initial focus is the development of next generation therapeutics to improve outcomes with people with blood cancers.

 

  • Innovative IV Forms
  • Novel Oral Forms
  • Combo Products
  • Patient-Focused
  • Less Toxicity
  • Greater Stability
  • Lower Total Cost of Treatment
0 +

Daily New Cases

0 +

Annual Deaths

0 +

Children Living with Leukemia

0 %

Case Increase by 2030

OUR TEAM

Leadership

Our team has over 160 years of collective experience in launching businesses and pharmaceuticals.

Exinda Therapeutics

© Exinda Therapeutics LLC, 2024. All Rights Reserved.

Privacy Policy